Radezolid

Radezolid

Skeletal formula of radezolid
Systematic (IUPAC) name
N-{[(5S)-3-(2-fluoro-4′-{[(1H-1,2,3-triazol-5-ylmethyl)amino]methyl}biphenyl-4-yl)-2-oxo-1,3-oxazolidin-5-yl]methyl}acetamide
Clinical data
Routes of administration	Intravenous infusion, oral
Legal status
Legal status	Investigational
Identifiers
CAS Number	869884-78-6
ATC code	none
PubChem	CID 11224409
ChemSpider	9399462
Chemical data
Formula	C22H23FN6O3
Molar mass	438.455 g/mol[[]]

Radezolid (INN, codenamed RX-1741) is a novel oxazolidinone antibiotic being developed by Rib-X Pharmaceuticals, Inc. for the treatment of serious multi-drug–resistant infections. Radezolid has completed two phase-II clinical trials. One of these clinical trials was for uncomplicated skin and skin-structure infections (uSSSI) and the other clinical trial was for community acquired pneumonia (CAP).

References

• Hanselmann R, Job G, Johnson G, Lou R, Martynow JG, Reeve MM (2009). "Synthesis of an antibacterial compound containing a 1,4-substituted 1H-1,2,3-triazole- a scaleable alternative to the "click" reaction"". Organic Process Research and Development. doi:10.1021/op900252a. CS1 maint: Multiple names: authors list (link)

External links

• Radezolid at Rib-X Pharmaceuticals